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Abstract: Ovarian cancer is the foremost cause of gynecological cancer death in the developed world,
as it is usually diagnosed at an advanced stage. In this paper we discuss current issues, the efficacy
and problems associated with ovarian cancer screening, and compare the characteristics of ovarian
cancer subtypes. There are two types of ovarian cancer: Type I carcinomas, which are slow-growing,
indolent neoplasms thought to arise from a precursor lesion, which are relatively common in Asia;
and Type II carcinomas, which are clinically aggressive neoplasms that can develop de novo from
serous tubal intraepithelial carcinomas (STIC) and/or ovarian surface epithelium and are common in
Europe and the USA. One of the most famous studies on the subject reported that annual screening
using CA125/transvaginal sonography (TVS) did not reduce the ovarian cancer mortality rate in the
USA. In contrast, a recent study in the UK showed an overall average mortality reduction of 20% in
the screening group. Another two studies further reported that the screening was associated with
decreased stage at detection. Theoretically, annual screening using CA125/TVS could easily detect
precursor lesions and could be more effective in Asia than in Europe and the USA. The detection of
Type II ovarian carcinoma at an early stage remains an unresolved issue. The resolving power of
CA125 or TVS screening alone is unlikely to be successful at resolving STICs. Biomarkers for the
early detection of Type II carcinomas such as STICs need to be developed.
Keywords: subtypes; two types of ovarian cancer; ovarian cancer screening; CA125;
transvaginal sonography
1. Introduction
Ovarian cancer is the foremost cause of gynecological cancer death and is overall one of the most
frequent causes of fatal malignancy in women [1]. The symptoms are often nonspecific, hampering
early detection, so the majority of patients present with advanced-stage disease.
Screening is defined as the application of a test or a combination of tests to an asymptomatic
at-risk population to detect a disease at an earlier and more curable stage. In 2011, an examination of
a screening program for prostate, lung, colorectal, and ovarian cancer (PLCO) in the USA revealed that
annual screening using CA125/transvaginal sonography (TVS) did not markedly reduce the ovarian
cancer mortality rate [2,3]. While this finding suggests that it is not possible to detect ovarian cancer at
an earlier curable stage, it is possible to question the validity of these data.
Recently, the characteristics of several subtypes of ovarian cancer have been elucidated by the
findings from histopathological, molecular, and genetic studies. Ovarian cancer can be roughly divided
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into two broad categories: Type I, in which precursor lesions in the ovaries have clearly been described;
and Type II, in which such lesions have not been clearly described and tumors may develop de novo
from the tubal and/or ovarian surface epithelium [4]. Understanding these characteristics is important
in the effort to reduce ovarian cancer mortality.
This study first describes the characteristics of the subtypes of ovarian cancer and the results of
several large-scale studies of ovarian cancer screening. We discuss current issues, the efficacy and
problems associated with ovarian cancer screening, and make comparisons of the characteristics of
ovarian cancer subtypes.
2. Ovarian Carcinoma Types
2.1. Type I Carcinoma
Type I carcinomas are generally slow-growing indolent neoplasms, and their precursor lesions in
the ovaries have been clearly described [4].
2.1.1. Endometrioid Carcinoma and Clear Cell Carcinoma
Clear cell and endometrioid carcinomas are believed to arise from endometriosis of the ovary.
Among malignant transformation cases of endometriotic cyst, serial transvaginal ultrasonography
(USG) examinations revealed an increase in the cyst size [5]. Increased risks of ovarian carcinoma
arising from endometriosis were associated with infertility, early menarche, and late menopause [6].
Pathologically, the co-existence of ovarian carcinoma and endometriosis is frequently observed, and in
such cases endometriosis is called “atypical endometriosis”, a putative precursor lesion including
atypia of the cell nucleus [7].
Carcinogenesis of endometrioid and clear cell carcinomas arising from endometriotic cysts is
significantly influenced by the microenvironment in the precursors [8]. The content of an endometriotic
cyst (including free iron in old blood) is thought to be associated with cancer development through
the induction of persistent oxidative stress [9]. The epithelial cells in the cyst are exposed to oxidative
stress and hypoxia. Thus, they are subject to increased cellular and DNA damage, have less efficient
DNA repair, and are easily transformed [10,11].
Somatic mutations in the ARID1A tumor-suppressor gene have been frequently identified in clear
cell carcinoma. BAF250a encoded by ARID1A is a member of the SWItch/sucrose nonfermentable
(SWI/SNF) complex. We recently reported that clear cell carcinomas exhibiting the loss of one or
multiple SWI/SNF complex subunits demonstrated aggressive behaviors and poor prognosis [12].
2.1.2. Mucinous Carcinoma
A subset of mucinous carcinomas is thought to develop in association with ovarian benign
teratomas; however, the majority of mucinous carcinomas do not show any teratomatous
components [13,14]. Other theories of an ontogeny include origin from mucinous metaplasia of surface
epithelial inclusions, endometriosis, and Brenner tumors [5,14]; however, these observations are
relatively uncommon, except for Müllerian endocervical mucinous or mixed borderline tumors [15,16].
Morphological transitions from cystadenoma to a mucinous borderline tumor (MBT) to
intraepithelial carcinoma and invasive carcinoma have occasionally been observed [17]. An increasing
frequency of KRAS mutations at codons 12 and 13 has been reported in cystadenomas, MBTs,
and mucinous carcinomas [18–21]. These findings support the hypothesis of the “mucinous
adenoma–carcinoma sequence” [17,22] and the view that mucinous carcinomas may develop in
a step-wise fashion from mucinous cystadenomas and MBTs.
2.1.3. Low-Grade Serous Carcinoma
Low-grade serous carcinomas are very rare tumors. They are genetically stable and are
characterized by their low number of genetic mutations; therefore, they develop slowly from the
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precursors and behave in an indolent fashion. They are also thought to grow in a step-wise
fashion from benign serous cystadenoma to serous borderline tumors (SBTs), and then to low-grade
serous carcinoma.
p53 mutations are uncommon in low-grade serous carcinoma [23]. These carcinomas have a DNA
content and level of copy number alterations that closely resembles that of SBTs [24,25].
One theory of the origin of these tumors is that they are derived from ovarian epithelial inclusions
that have undergone Müllerian metaplasia [26]. The exposure of the mesothelial cells to the ovarian
stromal microenvironment may result in transformation to Müllerian epithelium.
Another theory is that serous tumors may be derived from a secondary Müllerian system,
arising from the embryological remnants of the proximal Müllerian ducts located within the ovarian
hilm [27,28]. However, a new theory suggests that low-grade serous carcinoma may be derived from
the fallopian tube. The premise is that shed tubal epithelial cells can implant on the ovarian surface
epithelium, followed by the formation of inclusion cysts and transforming serous carcinoma [29,30].
2.2. Type II Carcinoma
Type II carcinomas are clinically aggressive neoplasms and may develop de novo from the tubal
and/or ovarian surface epithelium.
High-Grade Serous Carcinoma
High-grade serous carcinomas account for 68% of ovarian cancer and have the worst prognosis,
as they are high-grade clinically aggressive neoplasms that are usually diagnosed at an advanced stage.
They show TP53 gene mutations in nearly 80% of cases [31–34] and have a high Ki67 proliferation index
(50%–75%). Chromosomal rearrangements are common and associated with gene instability. Mutations
in the BRCA 1 and 2 genes are associated with 90% of hereditary high-grade serous carcinoma cases [35].
Recently, analyses of gene expression microarray data from The Cancer Genome Atlas (TCGA)
project have revealed that high-grade serous carcinoma can be classified into one of four gene
expression subtypes: mesenchymal, immunoreactive, proliferative, and differentiated [36,37].
Our group reported that the progression-free and overall survival were best in the immunoreactive
group, whereas the overall survival was worst in the mesenchymal transition group (p < 0.001 for
each) [38]. Expression of vascular endothelial growth factor (VEGF) inhibits tumor immunity through
the accumulation of myeloid-derived suppressor cells, and contributes to poor prognosis [39].
These tumors may develop de novo from the tubal and/or ovarian surface epithelium. In 2001,
Piek et al. [40] found new transformations from hyperplastic to dysplastic lesions on tubal segments
removed from women who had either BRCA mutations or a strong family history of ovarian
carcinoma and underwent a risk-reducing bilateral salpingo-oophorectomy (BSO). These dysplastic
lesions within the tubal epithelium are termed “serous tubal intraepithelial carcinomas” (STIC) and
microscopic disease.
A very early abnormality termed “secretory cell outgrowths” (SCOUTs) was recently
reported in tubal epithelia [41]. The TP53 signatures were the next earliest entities, and have
an immunohistochemical definition of “p53-positive with a low proliferative index (Ki67 < 10%)”.
Developing later were “serous tubal intraepithelial lesions” (STILs) [42], also known as “transitional
intraepithelial lesions of the tube” (TILTs) by some authors. These have proliferative p53 signatures,
tubal dysplasia, and even tubal epithelial atypia [40,43]. Lastly, these turned into STICs; thus, STICs
appear to be associated with the development of serous carcinoma.
It was recently reported that the junction of the fallopian tube epithelium with the mesothelium
of the tubal serosa might be a potential site for carcinogenesis [44]. Carcinomas arising from this
junctional zone can easily invade the extensive lymphovascular system under the tubal epithelium
and rapidly spread throughout the abdominal cavity.
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In contrast, ovarian hilum cells have shown increased transformation potential after the
inactivation of tumor suppressor genes transformation-related protein 53 (Trp53) and retinoblastoma 1
(Rb1) in mice [45]. These stem cells may also be the origin of high-grade serous carcinoma.
3. Large-Scale Studies of Ovarian Cancer Screening
Ovarian cancer screening was once thought to be ineffective, but has recently been reported to
result in a better prognosis than without screening [46].
3.1. A Screening Program for Prostate, Lung, Colorectal, and Ovarian Cancer
One large-scale study of ovarian cancer screening examined a screening program for prostate,
lung, colorectal, and ovarian cancer (PLCO) in the USA, performed using a randomized controlled
trial (RCT) [2,3]. The annual screening in this study was performed by transvaginal sonography and
CA125 level measurements.
The PLCO screening arm involved 78,216 women receiving either annual screening (n = 39,105)
or the usual care (n = 39,111). Ovarian cancer was diagnosed in 212 patients (0.54%) in the screening
group and 176 patients (0.45%) in the standard care group. The stage distribution in the screening
group was as follows: 32 (15%) cases of Stage I disease, 15 (7%) cases of Stage II disease, 120 (57%)
cases of Stage III disease, and 43 (20%) cases of Stage IV disease, indicating that 77% of patients had
cancer at Stage III or higher. The distribution of cancer histologies included 116 (80%) cases of serous
carcinomas, five (3%) cases of mucinous carcinomas, 19 (13%) cases of endometrioid carcinomas, and
six (4%) cases of clear cell carcinomas, indicating that most cases involved serous cancers.
The authors concluded that annual screening did not reduce the ovarian cancer mortality rate
compared with standard care. Based on this report, ovarian cancer screening is not considered to
be effective.
3.2. Re-Analysis of the PLCO Screening Data
We obtained the authors’ datasets and performed a new analysis. We divided the patients who
were diagnosed with ovarian cancer into two groups. One group included 101 patients whose ovarian
cancers were detected through annual screening (CA125 and/or TVS) or within one year after screening.
The other group included 344 patients in the screening group whose ovarian cancers were found at
more than one year after screening due to the patient experiencing symptoms, as well as patients
in the no screening and control groups. We previously reported these results [47]. The prognosis
was significantly better in the patients in the former group than in those in the latter group (median
survival: 6.1 vs. 3.3 years, p = 0.0017). Additionally, the first group contained significantly fewer Stage
IV cases than the second group (13% vs. 29%, respectively, p = 0.005).
We identified two weaknesses in the PLCO screening: the group undergoing annual screening
included many women who never received screening, and many patients with ovarian cancer in the
screening group were diagnosed incidentally more than one year after screening, and as such could
not be related to the direct effect of screening.
3.3. The United Kingdom Collaborative Trial of Ovarian Cancer Screening
The United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) is an RCT of
202,638 women (control: 101,359; multimodal screening (MMS): 50,640; TVS alone: 50,639) [48–50].
The MMS protocol included annual CA125 screening interpreted using a patented “Risk of Ovarian
Cancer” algorithm (ROCA) with TVS as a second-line test [51,52]. Ovarian cancer was diagnosed in
38 (0.08%) patients in the MMS group and 32 (0.06%) patients in the TVS group. The distribution of
the cancer histologies was similar to that of the PLCO group. The distribution of the cancer stages in
the MMS group was as follows: 17 (45%) patients with Stage I disease, 2 (5%) patients with Stage II
disease, 19 (50%) patients with Stage III disease, and 0 (0%) patients with Stage IV disease, which was
similar to that of the TVS group. Recently, a UK team reported on the final mortality, citing an overall
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average mortality reduction of 20%, and a reduction of 8% in years 0–7 and 28% in years 7–14 in
the MMS group, compared with the no screening group [46]. They suggested that this late effect of
screening was predictable given the unavoidable time interval from randomization to diagnosis and
finally death. Therefore, their interpretation was that MMS screening was more effective after seven
years of screening.
Very recently, Pavik pointed out two problems raised by the work of the UKCTOCS [53].
The UKCTOCS results from the analysis using the Cox proportional hazards model and the
Royston–Parmar flexible parametric model indicated only small differences between the MMS and
TVS modalities that were not statistically significant (estimated mortality reduction for years 7–14:
23% MMS vs. 21% TVS with the Royston–Parmar flexible parametric model). Another problem was
that an expected lack of CA125 expression (20%) produces CA125-negative ovarian carcinomas that
cannot be expected to be detected in the MMS group.
3.4. The Kentucky Screening Study
In the Kentucky Screening Study, single-arm annual TVS screenings of 37,293 women was
performed [54,55]. The stage distribution of the 47 invasive ovarian cancers was as follows: 22 (47%)
Stage I lesions, 11 (23%) Stage II lesions, 14 (30%) Stage III lesions, and 0 (0%) Stage IV lesions,
with a 70% rate of Early-Stage (I/II) disease. The distribution of cancer histologies included 38% with
serous carcinomas, 2% with mucinous carcinomas, 26% with endometrioid carcinomas, 4% with clear
cell carcinomas, and 30% with others. The survival rate at five years of the patients with ovarian cancer
in the annual screening group was better than that of the patients with ovarian cancer who did not
undergo screening (74.8% ± 6.6% vs. 53.7% ± 2.3%, p < 0.001). Histologically, compared with the
PLCO data, the rate of serous carcinomas was relatively low and the rate of endometrioid carcinomas
was relatively high.
The authors concluded that annual TVS screening was associated with a decreased stage at
detection, as well as a decrease in the case-specific ovarian cancer mortality. However, this study was
not an RCT.
3.5. The Japanese Study
In Japan, the results of the Shizuoka Cohort Study of Ovarian Cancer Screening have been
reported [56]. This study was an RCT of 82,487 low-risk postmenopausal women (intervention group:
41,688, control group: 40,799) who were screened using annual TVS and CA125 levels. The total
number of cases of ovarian cancer in the screening group was 27 (0.06%). The stage distribution in the
intervention group was as follows: 17 (63%) cases of Stage I disease, 1 (4%) case of Stage II disease,
7 (26%) cases of Stage III disease, and 2 (7%) cases of Stage IV disease. The distribution of the cancer
histologies included 8 (30%) cases of serous carcinomas, 4 (15%) cases of mucinous carcinomas, 5 (19%)
cases of endometrioid carcinomas, 9 (33%) cases of clear cell carcinomas, and 1 (4%) case of “other”.
Histologically, most of these cases involved cancers other than serous carcinoma. The proportion of
Stage I/II ovarian cancers was higher in the screening group (67%) than in the control group (44%).
The rate of complete surgical excision was higher in the screening group (21; 78%) than in the control
group (15; 47%) (p = 0.018). However, the mortality rates are unknown, which again is problematic.
4. Differing Histological Subtypes of Ovarian Carcinoma among Races
In Europe, the USA, and Asia, there are significant differences in the rates of histological subtypes
of ovarian carcinoma [57–62]. As we reported previously, the rate of aggressive ovarian cancer such
as high-grade serous cancer (Type II) is significantly higher in Europe and the USA than in Asia
(p < 0.001) [47]. For example, the rates of Type I vs. Type II are, 24% vs. 48% in Europe (including the
UK); 24% vs. 66% in Denmark; and 30% vs. 45% in the USA. Conversely, Type I carcinomas—indolent
carcinomas arising from precursors—are relatively common in Asia. For example, the rates of
Type I vs. Type II are 53% vs. 33% in Japan; 58% vs. 24% in Hong Kong; and 66% vs. 34% in
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Korea. These results theoretically imply that ovarian cancer screening using CA125/TVS would be
more effective in Asia than in Europe and the USA, as the precursors or ovarian cancer can be detected
at an earlier stage, thereby reducing the mortality.
5. Conclusions
We presented characteristics of subtypes of ovarian cancer, summarized in Table 1. Type I
carcinomas are generally slow-growing indolent neoplasms, and their precursor lesions in the ovaries
have clearly been described and are easily detected. Conversely, Type II carcinomas are clinically
aggressive neoplasms and may develop de novo from the tubal and/or ovarian surface epithelium.
The efficacy of ovarian cancer screening depends on the subtypes of ovarian cancer. Type I ovarian
carcinomas are relatively common in Asia, while Type II ovarian carcinomas are relatively common
in Europe and the USA. Therefore, annual ovarian cancer screening may improve the prognoses in
Asia to a substantially greater degree than in Europe and the USA, as precursors or early-stage Type I
ovarian carcinomas can be detected using CA125/TVS in those regions. Furthermore, it is possible to
improve the prognosis or induce down-staging of Type II ovarian carcinomas, even in Europe and
the USA. The detection of Type II ovarian carcinoma at an early stage remains an unresolved issue.
We have likely failed to notice the presence of STICs using CA125/TVS screening alone, as neither
method showed positive findings in women with STICs. Biomarkers for the early detection of Type II
carcinomas such as STICs are therefore urgently needed [53].
Table 1. Characteristics of two types of ovarian carcinoma.
Type I Type II
Behavior Indolent Aggressive
Genetic instability Not very unstable Very unstable
TP 53 mutation Low High
BRCA1/BRCA2 mutation Low High
Ki 67 proliferative index 10%–15% 50%–75%




Precursor Benign cyst s/o Tubal dysplasia
(de novo starting)
Discover a precursor Easy Difficult
Incidence Asia > Europe, USA Europe, USA > Asia
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